Press releases
- Glaukos Announces the Release of its 2023 Sustainability Report
- Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
- Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
- Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
- Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
- Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 93.00 |
---|---|
High | 94.50 |
Low | 93.00 |
Bid | 94.00 |
Offer | 94.50 |
Previous close | 93.50 |
Average volume | 5.33 |
---|---|
Shares outstanding | 49.98m |
Free float | 48.22m |
P/E (TTM) | -- |
Market cap | 5.04bn USD |
EPS (TTM) | -2.78 USD |
Data delayed at least 15 minutes, as of Apr 24 2024.
More ▼